Jasper's cell therapy conditioning agent shows promise in small study; ViiV's Rukobia sees approval in Europe
Jasper Therapeutics, broadly aimed at making cell therapy safer, released preliminary data for its complement to stem cell transplants on Monday.
The biotech is running an open-label Phase I trial of its lead program JSP191, an anti-CD117 monoclonal antibody that targets the stem cell factor receptor, as a conditioning agent in patients aged 65 to 74 with myelodysplastic syndromes or acute myeloid leukemia that are undergoing blood cell transplantation. Six patients have received the treatment thus far, and all six showed successful engraftment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.